+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study



Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study



Respiratory Medicine 147: 37-43



N-acetylcysteine (NAC) 600 mg twice daily is a well-tolerated oral antioxidant mucolytic that reduces the risk of moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations. PANTHEON was one of the largest studies to evaluate NAC in COPD. It recruited current, ex- and never-smokers, concomitantly treated with other medications, and used a symptom-based definition of COPD exacerbations rather than the conventional healthcare resource utilisation (HCU) criteria. This manuscript reports post-hoc analyses of the PANTHEON dataset investigating whether smoking status or use of concomitant medications influenced the efficacy of NAC in terms of reducing exacerbations, defined according to HCU. Compared with placebo (N = 482), NAC (N = 482) reduced the rate of HCU events by 20% (p = 0.0027), with a larger effect in current/ex-smokers (23%; p < 0.01). In patients receiving NAC and long-acting inhaled bronchodilator(s) but no ICS, there was a 60% reduction in the rate of exacerbations compared to those receiving placebo, long-acting bronchodilator(s) and ICS (p < 0.0001). Overall, these post-hoc hypothesis-generating analyses confirm that NAC reduces the rate of COPD exacerbations, particularly in patients with COPD who have a significant smoking history, and in those not treated with ICS. NAC may provide an alternative to ICS-containing combinations in these patient subgroups. Chinese Clinical Trials Registry, ChiCTR-TRC-09000460.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446779

Download citation: RISBibTeXText

PMID: 30704697

DOI: 10.1016/j.rmed.2018.12.014


Related references

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet. Respiratory Medicine 2(3): 187-194, 2014

High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clinical Drug Investigation 25(6): 401-408, 2007

Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. Copd 11(3): 351-358, 2015

The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review. Heart and Lung 46(2): 120-128, 2017

High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 11: 799-807, 2017

High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. Copd 10(2): 164-171, 2013

Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respiratory Medicine 132: 31-41, 2018

N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. Copd 3(4): 195-202, 2007

N-Acetylcysteine and Exacerbations of Chronic Obstructive Pulmonary Disease. Copd Journal of Chronic Obstructive Pulmonary Disease 3(4): 195-202, 2006

High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review. Chronic Obstructive Pulmonary Diseases 3(2): 580-588, 2016

U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration; International Review of Thoracic Diseases 82(4): 320-327, 2012

Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health and Quality of Life Outcomes 7: 69, 2009

High-dose N-acetylcysteine in chronic obstructive pulmonary disease, prone positioning in acute respiratory distress syndrome, and continuous positive airway pressure and exhaled nitric oxide in obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine 189(2): 223-224, 2014

Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344. Bmc Pulmonary Medicine 4: 13, 2004

Comparison of global initiative for chronic obstructive pulmonary disease 2013 classification and body mass index, airflow obstruction, dyspnea, and exacerbations index in predicting mortality and exacerbations in elderly adults with chronic obstructive pulmonary disease. Journal of the American Geriatrics Society 63(2): 244-250, 2015